Editorial: Clinical Paths for Soluble Epoxide Hydrolase Inhibitors
Saved in:
Main Authors: | John D. Imig (Author), Christophe Morisseau (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2020-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical Paths for Soluble Epoxide Hydrolase Inhibitors
Published: (2020) -
Soluble Epoxide Hydrolase Deletion Limits High-Fat Diet-Induced Inflammation
by: Karen M. Wagner, et al.
Published: (2021) -
2-(Piperidin-4-yl)acetamides as Potent Inhibitors of Soluble Epoxide Hydrolase with Anti-Inflammatory Activity
by: Juan Martín-López, et al.
Published: (2021) -
Pharmaceutical Effects of Inhibiting the Soluble Epoxide Hydrolase in Canine Osteoarthritis
by: Cindy B. McReynolds, et al.
Published: (2019) -
The Soluble Epoxide Hydrolase Inhibitor AR9281 Decreases Blood Pressure, Ameliorates Renal Injury and Improves Vascular Function in Hypertension
by: Sean Shaw, et al.
Published: (2009)